Literature DB >> 12480022

Serum phosphate abnormalities in the emergency department.

Joseph R Shiber1, Amal Mattu.   

Abstract

Abnormalities in serum phosphate levels are more prevalent in certain subsets of Emergency Department patients than in the general population. Patients with diabetic ketoacidosis, chronic obstructive pulmonary disease, alcoholism, malignancy, and renal failure are at increased risk. Multiple factors, including nutritional intake, medications, renal or intestinal excretion, and cellular redistribution, are potential etiologies. The clinical manifestations of mild hypophosphatemia or hyperphosphatemia are typically minor and nonspecific (myalgias, weakness, anorexia). When the imbalance is severe, critical complications may occur (tetany, seizures, coma, rhabdomyolysis, respiratory failure, ventricular tachycardia). Mild asymptomatic hypophosphatemia can be treated with oral phosphate supplementation (15 mg/kg daily) on an outpatient basis. Patients with severe or symptomatic hypophosphatemia should be treated with IV phosphate therapy (0.08-0.16 mg/kg over 6 h) and admitted for monitoring and subsequent serum electrolyte testing. Mild asymptomatic hyperphosphatemia is commonly managed in renal failure by limiting dietary intake and reducing absorption with phosphate-binding salts. Hemodialysis may be required for severe hyperphosphatemia with symptomatic hypocalcemia.

Entities:  

Mesh:

Year:  2002        PMID: 12480022     DOI: 10.1016/s0736-4679(02)00578-4

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  17 in total

Review 1.  The emergence of phosphate as a specific signaling molecule in bone and other cell types in mammals.

Authors:  Solmaz Khoshniat; Annabelle Bourgine; Marion Julien; Pierre Weiss; Jérôme Guicheux; Laurent Beck
Journal:  Cell Mol Life Sci       Date:  2010-09-17       Impact factor: 9.261

2.  In vitro bactericidal activity of human beta-defensin 3 against multidrug-resistant nosocomial strains.

Authors:  Giuseppantonio Maisetta; Giovanna Batoni; Semih Esin; Walter Florio; Daria Bottai; Flavia Favilli; Mario Campa
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Approach to the hypophosphatemic patient.

Authors:  Erik A Imel; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2012-03       Impact factor: 5.958

4.  Effects of a 250-mL enema containing sodium phosphate on electrolyte concentrations in healthy volunteers: An open-label, randomized, controlled, two-period, crossover clinical trial.

Authors:  Belén Sédaba; Josh R Azanza; Miguel A Campanero; Emilio Garcia-Quetglas; Maria Josh Muñoz; Santiago Marco
Journal:  Curr Ther Res Clin Exp       Date:  2006-09

Review 5.  The Causes of Hypo- and Hyperphosphatemia in Humans.

Authors:  Eugénie Koumakis; Catherine Cormier; Christian Roux; Karine Briot
Journal:  Calcif Tissue Int       Date:  2020-04-13       Impact factor: 4.333

6.  Inherited disorders of calcium and phosphate metabolism.

Authors:  Jyothsna Gattineni
Journal:  Curr Opin Pediatr       Date:  2014-04       Impact factor: 2.856

7.  Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.

Authors:  Regina Goetz; Yuji Nakada; Ming Chang Hu; Hiroshi Kurosu; Lei Wang; Teruyo Nakatani; Mingjun Shi; Anna V Eliseenkova; Mohammed S Razzaque; Orson W Moe; Makoto Kuro-o; Moosa Mohammadi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

8.  Case-control study and case series of pseudohyperphosphatemia during exposure to liposomal amphotericin B.

Authors:  Nicole M Bohm; Katherine C Hoover; Amy E Wahlquist; Yusheng Zhu; Juan Carlos Q Velez
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

Review 9.  Phosphate Metabolism in Health and Disease.

Authors:  Munro Peacock
Journal:  Calcif Tissue Int       Date:  2020-04-07       Impact factor: 4.333

10.  Rhabdomyolysis updated.

Authors:  G Efstratiadis; A Voulgaridou; D Nikiforou; A Kyventidis; E Kourkouni; G Vergoulas
Journal:  Hippokratia       Date:  2007-07       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.